Suicide gene stem cells take aim at glioblastoma

NCT ID NCT07143812

Recruiting now Disease control Sponsor: CHA University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment called MSC11FCD for people with newly diagnosed glioblastoma, an aggressive brain cancer. The treatment uses donor stem cells that carry a 'suicide gene' and are injected into the brain during surgery to kill any remaining cancer cells. The study will enroll 10 patients to check if the treatment is safe and to find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MSC11FCD (stem cells with a suicide gene)
What this could lead to: If it works, this could point toward a new way to kill leftover tumor cells after surgery and delay glioblastoma recurrence.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The approach may not work in humans, and there are risks from the surgery and the stem cells themselves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA (GBM) NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Bundang CHA Medical Center
RECRUITING

Seongnam, Kyunggido, 13496, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.